At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,008 enrolled
Drug / intervention
prasugrel or ticagrelor +1 moredrug
Likely dose
prasugrel or ticagrelor 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
In Brief
A Phase 3 clinical trial evaluating prasugrel or ticagrelor and Clopidogrel for Platelet Inhibition and Coronary Stent Implantation. Completed, enrolled 1,008 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Inhibition, Coronary Stent Implantation
CountriesAustria
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJan 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartJul 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago
Interventions
prasugrel or ticagrelordrug
prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
Clopidogreldrug
clopidogrel 75mg od for 12 month